Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data - PubMed
7 days ago
- #SGLT2 inhibitors
- #diabetes
- #hematologic malignancies
- SGLT2 inhibitors may reduce the risk of hematologic malignancies in diabetic patients.
- The study used Japanese claims data from 2005 to 2023, comparing SGLT2 inhibitor users (N=158,877) and non-users (N=118,678).
- Propensity score matching resulted in 102,478 matched patients per group.
- Hematologic malignancy incidence was lower in the SGLT2 inhibitor group (HR=0.73, P<0.001).
- Lymphoma incidence was significantly lower (HR=0.71, P=0.003), but leukemia showed no clear difference (HR=0.76, P=0.06).
- Lymphocytic leukemia incidence was lower (HR=0.44, P=0.04), while myeloid leukemia showed no significant difference (HR=0.76, P=0.12).
- Acute myeloid leukemia (AML) incidence was notably lower in the SGLT2 inhibitor group (HR=0.34, P=0.001).
- The study suggests SGLT2 inhibitors could be a preventive strategy for hematologic malignancies in diabetes patients.